A comparison of interview methods to ascertain fluoroquinolone exposure before tuberculosis diagnosis

Epidemiology and Infection

Volumn 143, Issue 5, 2015, Pages 960-965

  Van Der Heijden, Y F ^a,b   Maruri, F ^a,b   Holt, E ^c   Mitchel, E ^a   Warkentin, J ^c   Sterling, T R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c TENNESSEE DEPARTMENT OF HEALTH   (United States)

Author keywords

Infectious disease; tuberculosis (TB)

Indexed keywords

QUINOLINE DERIVED ANTIINFECTIVE AGENT; ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; CONTROLLED STUDY; DRUG DATABASE; DRUG USE; FEMALE; FLUOROQUINOLONE ASSESSMENT FORM; GOLD STANDARD; HUMAN; INTERMETHOD COMPARISON; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PREDICTIVE VALUE; QUESTIONNAIRE; RELIABILITY; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; UNITED STATES; ANAMNESIS; COMPARATIVE STUDY; DELAYED DIAGNOSIS; FACTUAL DATABASE; MEDICAL RECORD; MIDDLE AGED; PHARMACY; PROCEDURES; TUBERCULOSIS, PULMONARY;

ADULT; ANTI-BACTERIAL AGENTS; DATABASES, FACTUAL; DELAYED DIAGNOSIS; DRUG RESISTANCE, BACTERIAL; FEMALE; FLUOROQUINOLONES; HUMANS; INTERVIEWS AS TOPIC; MALE; MEDICAL HISTORY TAKING; MEDICAL RECORDS; MIDDLE AGED; PHARMACIES; SURVEYS AND QUESTIONNAIRES; TENNESSEE; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 84924370891     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268814003136     Document Type: Review

References (13)

1. Shapiro DJ, et al. Antibiotic prescribing for adults in ambulatory care in the USA, 2007-09. Journal of Antimicrobial Chemotherapy 2014; 69: 234-240.
2. Gaba PD, et al. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease. Archives of Internal Medicine 2007; 167: 2317-2322.
3. Devasia RA, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. American Journal of Respiratory and Critical Care Medicine 2009; 180: 365-370.
4. Ginsburg AS, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clinical Infectious Diseases 2003; 37: 1448-1452.
5. Wang JY, et al. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas. Thorax 2006; 61: 903-908.
6. van der Heijden YF, et al. Fluoroquinolone exposure prior to tuberculosis diagnosis is associated with an increased risk of death. International Journal of Tuberculosis and Lung Disease 2012; 16: 1162-1167.
7. Falzon D, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. European Respiratory Journal 2011; 38: 516-528.
8. Conde MB, et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009; 373: 1183-1189.
9. Dooley KE, et al. Empiric treatment of communityacquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis. Clinical Infectious Diseases 2002; 34: 1607-1612.
10. Long R, et al. Empirical treatment of communityacquired pneumonia and the development of fluoroquinolone-resistant tuberculosis. Clinical Infectious Diseases 2009; 48: 1354-1360.
11. Stolley PD, et al. Agreement rates between oral contraceptive users and prescribers in relation to drug use histories. American Journal of Epidemiology 1978; 107: 226-235.
12. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977; 33: 159-174.
13. Hicks LA, Taylor TH Jr., Hunkler RJ. U.S. Outpatient antibiotic prescribing, 2010. New England Journal of Medicine 2013; 368: 1461-1462.